Month: July 2020

AGOURA HILLS, Calif., July 27, 2020 (GLOBE NEWSWIRE) — Mateon Therapeutics (OTC.QB: MATN) announced the closing of the 1st tranche of financing related to the Mateon operations and spinoff of its EdgePoint AI, Inc. (“EdgePoint”, a Delaware Corporation and a division of Mateon). JH Darbie & Co., Inc. is acting as the exclusive placement agent for the Offering. The Offering consists of a minimum of 40 units on a best effort all or none basis and a maximum of up to 100 units on a best effort basis at a price per unit of $50,000 (the “Units”).  This initial closing is for the sale of 40 Units.  Each Unit allows the Unit holder to purchase 25,000 shares of the Common Stock of EdgePoint (Mateon’s artificial intelligence (“AI”) division) and one note issued by Mateon (the “Note”). Each Note is convertible into up to 25,000 shares...

NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that preclinical results of TNX-1900 (oxytocin solution for intranasal delivery) will be presented in a poster at the American Academy of Neurology’s first-ever Sports Concussion Conference. The research was sponsored by Trigemina, Inc. and in June Tonix acquired the assets of Trigemina including certain rights to the data described on the poster.  Dr. Shashidhar Kori was formerly chief medical officer of Trigemina.  Dr. David Yeomans and Dr. Michael Klukinov are on the faculty of Stanford University.  Dr. Kori and Dr. Yeomans are currently consultants to Tonix. The virtual meeting is being held July 31 and August 1, 2020.Details of the poster presentation:Title: ...

紐約洲水牛城, July 27, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq: ATNX) 是一家致力於研究、開發和商業化治療癌症和相關疾病新療法的的全球生物製藥公司，其今天宣佈將在 2020 年 8 月 6 日（星期四）市場開放前，發佈 2020 年第二季度財務業績，且會於東岸時間上午 8 時提供現場電話會議和聲音網絡講解財務報告及提供業務近況。若要參與本次會議，請在電話會議前十五分鐘致電 877-407-0784 （本地）或 201-689-8560 （國際），並提述會議驗証碼 13706637。現場電話會議和聲音網絡重播都可以在公司網站的投資者關係頁面上取得，網址為：http://ir.athenex.com/。關於 Athenex, Inc.創於 2003 年，Athenex, Inc. 是一家臨床階段的國際生物製藥公司，並致力成為研究、開發及將下一代癌症治療藥物商業化的領導者。Athenex 下設三個平台，分別為腫瘤創新平台、商業平台和全球供應鏈平台。公司現有的臨床產品系列源自四個不同平台的科技：(1) 以 p-糖蛋白抑制劑為基礎的 Orascovery；(2) Src 酶抑制劑；(3) 受體工程化 T 細胞 (TCR-T) 及 (4) 精氨酸消除療法。Athenex 的員工遍佈全球，致力透過開發更有效及耐受的治療來改善癌症病人的生活。Athenex 在紐約州的水牛城和克拉倫斯、德州的休斯頓、伊利諾伊州的芝加哥、香港、台灣的台北、中國的重慶、英國的曼徹斯特、危地馬拉的危地馬拉市及阿根廷的布宜諾斯艾利斯等多個地方，均設有辦事處。如欲了解更多資訊，請瀏覽 www.athenex.com。聯絡人Athenex, Inc.：Daniel Lang，執行董事企業發展及企業傳訊電郵：danlang@athenex.comJacqueline Li公司發展與投資者關係電郵：jacquelineli@athenex.com投資者關係：Tim...

BUFFALO, N.Y., July 27, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release second quarter 2020 financial results on Thursday, August 6, 2020, before the market opens, and host a conference call and live audio webcast 8:00am Eastern Time to discuss the financial results and provide a business update.To participate in the call, dial 877-407-0784 (domestic) or 201-689-8560 (international) fifteen minutes before the conference call begins and reference the conference passcode 13706637. The live conference call and replay can also be accessed via audio webcast at the Investor Relations section of the Company’s website, located at...

ZION, IL, July 27, 2020 (GLOBE NEWSWIRE) — Lifted Made, a wholly owned subsidiary of publicly traded Acquired Sales Corp. (OTC Pink: AQSP), is excited to announce its launch of the world’s first hemp-derived delta-8-THC nano-particle drops under Lifted Made’s flagship brand Urb Finest Flowers (Instagram @LiftedMade).Urb’s delta-8-THC nano drops are a flavored, water soluble tincture and beverage additive, and are federally legal. The nano drops are sold in a one ounce bottle and contain 333 mg. of delta-8-THC and less than 0.3% delta-9-THC. Currently, the product is available for purchase in three flavors: Go Grape, Let’s Mango, and Orange Dream. The nano drops retail for $34.99/bottle, and are available for purchase online at www.LiftedMade.com and in brick and mortar stores throughout the USA.Delta-8-THC is one of the many cannabinoids...

WILMINGTON, Del., July 27, 2020 (GLOBE NEWSWIRE) — Ashland Global Holdings Inc. (NYSE: ASH) today announced a definitive agreement to sell the company’s maleic anhydride business and manufacturing facility in Neal, West Virginia to AOC Materials LLC, for $100 million.Maleic anhydride is manufactured industrially on a large scale for applications in coatings and polymers. The maleic anhydride business was previously excluded from the sale of Ashland’s Composites business and the butanediol (BDO) manufacturing facility in Marl, Germany, to INEOS Enterprises. The transaction with AOC is expected to close prior to the end of calendar year 2020, contingent on customary regulatory approvals and standard closing conditions.“Today’s announcement furthers Ashland’s strategic focus to streamline our portfolio and to focus on specialty ingredients...

WATERLOO, Ontario, July 27, 2020 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that dnata, one of the world’s largest air services providers, is deploying Descartes Core Bluetooth Low Energy (BLE)™ readers across its global cargo operations to support the tracking of international mail, parcel and cargo shipments.“We rely on best-in-class facilities and state-of-the-art cargo handling technologies to provide over 150 airlines with premium services for approximately 3 million tonnes of cargo annually,” said Guillaume Crozier, Divisional Vice President Operations and Product Development at dnata. “The innovative Descartes solution is expected to help us further improve service efficiency as we move customers’ cargo smoothly from...

ROCKFORD, Mich., July 27, 2020 (GLOBE NEWSWIRE) — Wolverine World Wide, Inc. (NYSE: WWW) today announced that it expects to report its second quarter 2020 financial results on Wednesday, August 5, 2020, at approximately 6:30 a.m. ET.  Following the press release, the Company will host a conference call at 8:30 a.m. ET to review results and discuss current business trends.The conference call will be broadcast live and accessible under the “Investor Relations” tab at www.wolverineworldwide.com.  A replay of the conference call will be available at the Company’s website for a period of approximately 30 days.ABOUT WOLVERINE WORLDWIDEFounded in 1883 on the belief in the possibility of opportunity, Wolverine World Wide, Inc. (NYSE:WWW) is one of the world’s leading marketers and licensors of branded casual, active lifestyle,...

LA JOLLA, Calif., July 27, 2020 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an agreement with BioComo (President: Masayuki Fukumura, Mie prefecture, Japan;  http://www.biocomo.jp/) and Mie University (Mie prefecture, Japan) for joint development of a SARS-CoV-2 vaccine using BC-PIV, a human parainfluenza virus type 2 vector developed by BioComo and Tetsuya Nosaka, M.D., Ph.D., professor of the Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine.  MediciNova has been granted exclusive worldwide development rights to use BC-PIV for SARS-CoV-2 vaccine development from BioComo and Mie University.BC-PIV, an innovative non-transmissible viral...

Emergent will provide contract development and manufacturing services beginning in 2020 to produce drug substance at large scale for commercial supplyAgreement is valued at approximately $174 million through 2021 and brings the total AstraZeneca commitment to $261 millionParties may enter into additional commercial manufacturing commitments as the candidate progresses over three years through Emergent’s flexible capacity deployment modelGAITHERSBURG, Md., July 27, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed an agreement to provide contract development and manufacturing (CDMO) services for large-scale commercial drug substance manufacturing for AstraZeneca’s COVID-19 vaccine candidate, AZD1222. The agreement is valued at approximately $174 million through 2021 and follows an $87...